04:56
Unknown
IPCA Laboratories has entered into an agreement with Avik Pharmaceutical (Avik) to acquire 50% of its paid-up equity share capital, partly through purchase of equity shares from its existing shareholders and partly thru subscription to its fresh equity share capital on a preferential allotment basis, both aggregating to approximately Rs 6.51 crore.
Posted in: Indian Market Tips
0 comments:
Post a Comment